REGISTER IV · THE HANDLING RECORD
What the research says about KLOW dosing context
There is no validated human dose for the blend. What the record holds is a vial composition, component-level research doses, routes studied, and a clearance mismatch.
In plain words
There is no proven human dose for the KLOW peptide. That is the whole answer, and the rest is context. The research on the four peptides used very different amounts, by very different routes, mostly in animals — and you cannot add those up into one "KLOW dose." The vial people quote is an 80 mg total, but that number describes what is in the vial, not how much a person should use. The four peptides also clear the body at very different speeds, so no single schedule keeps them all active at once. This page covers dosage and research-handling context — the composition, the routes studied in the lab, the half-life mismatch and how the freeze-dried powder is mixed for handling. It does not tell anyone how much to use or where to inject, because no validated human protocol exists and this site does not provide one.
What the research says about KLOW dosing context
The canonical research vial is an 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, reconstituted with bacteriostatic water for laboratory handling. That figure describes the co-formulation, not a human dose. No validated human dosing exists for the blend, and component-level research doses differ widely by species and route and are not additive into a single "KLOW dose." In the component literature, for example, BPC-157 was tested at 10 microgram, 10 nanogram or 10 picogram per rat in the transected-Achilles model [2], and thymosin beta-4 stimulated keratinocyte migration at quantities as small as 10 picograms in vitro [1] — figures that describe animal and cell-culture research, not anything additive into a blend dose for a person.
Dosage and frequency in the research literature
No validated human dose or frequency exists for the KLOW blend. The component peptides also have markedly different reported half-lives — the tripeptides KPV and GHK-Cu clear far faster than the larger BPC-157, and the TB-500 fragment behaves differently from native thymosin beta-4 — which produces a pharmacokinetic mismatch within a single co-formulated vial [11]. In practical terms, no single dose-and-frequency schedule can keep all four components at matched exposures: whatever interval suits one peptide leaves another either cleared or accumulating. Because the blend has never been studied, there is no measured frequency, no titration schedule and no per-day milligram figure for human use to report — only the vial composition above.
Routes studied in the component literature
Across the component research, the four peptides have been administered by subcutaneous, intramuscular, intraperitoneal, topical (GHK-Cu), oral or targeted-delivery (KPV and BPC-157) and intra-articular (BPC-157) routes — all in animal models or laboratory settings [3][4]. BPC-157's tendon work used once-daily intraperitoneal injection in rats [2], and thymosin beta-4's wound work used topical and intraperitoneal routes [1]. No validated human administration route exists for the blend, and this catalogue does not provide human-injection instructions. The routes are recorded as research context — which species received which peptide by which route — not as a guide to use.
Reconstitution and stability notes
In laboratory handling the lyophilized (freeze-dried) blend is reconstituted with bacteriostatic water and the resulting solution typically refrigerated. One theoretical compatibility note belongs in the record: the copper(II) ion in GHK-Cu can participate in redox chemistry, which raises a compatibility and oxidation question when GHK-Cu is co-dissolved with the other three peptides in one vial. That has not been formally characterized for this mixture — it is a chemistry-level caveat, not a measured finding [4]. As context for KLOW reconstitution, this is handling information for laboratory work, not a preparation protocol for human use.
What the 80 mg figure does and does not mean
The KLOW peptide 80 mg label is a composition figure, not a dose. It records that the canonical vial holds 80 mg of peptide mass distributed as GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, with GHK-Cu accounting for about 62.5% of the mass [4]. Two things follow. First, the four peptides keep their separate molecular identities — they are co-dissolved, not combined into one 80 mg molecule, so there is no single molecular weight, CAS or PubChem identifier for the contents. Second, an 80 mg total mass tells a reader nothing about a human dose: the figure describes what is in the vial for laboratory handling, and component research doses (measured per kilogram of body weight in rats, or in picograms in cell culture) do not sum into it. Reading 80 mg as a use instruction is exactly the error this register is built to prevent.
Why no single schedule fits all four
The pharmacokinetic mismatch deserves its own entry because it is the structural reason the blend resists a tidy protocol. BPC-157 has a very short elimination half-life — under roughly 30 minutes in the formal pharmacokinetic study — and the tripeptides KPV and GHK-Cu clear even faster, while the TB-500 fragment behaves differently again from native thymosin beta-4 [11]. Co-formulating four peptides with mismatched clearance into one vial means any single interval optimizes for at most one of them. There is no measured human schedule to report, and the chemistry says one could not be derived from the vial composition alone; the components would need to be studied together, which they have not been.